Natural Capsules Limited , a prominent player in the capsule manufacturing industry, has announced its financial results for the second quarter and first half of the fiscal year 2025-26, revealing a mixed performance across its standalone and consolidated operations.

Standalone Performance

On a standalone basis, Natural Capsules Limited demonstrated resilience in its core business. The company reported a revenue from operations of Rs. 4,458.02 lakhs for the quarter ended September 30, 2025, marking a slight increase from the previous quarter. The net profit for Q2 stood at Rs. 281.05 lakhs, showing an improvement over the preceding quarter.

For the six-month period, the company's standalone performance was noteworthy:

Consolidated Results and Subsidiary Performance

The consolidated financial picture, however, presented challenges:

The significant disparity between standalone profit and consolidated loss is primarily attributed to the performance of the company's subsidiary, Natural Biogenex Private Limited. The subsidiary, which commenced commercial operations on March 31, 2025, is yet to achieve its full revenue potential, contributing to higher consolidated losses.

Strategic Decision on Rights Issue

The Board of Directors of Natural Capsules Limited has decided not to subscribe to the rights issue of Natural Biogenex Private Limited. This decision was attributed to cash flow commitments from ongoing projects, indicating a strategic focus on managing financial resources effectively.

Segment Performance

The company's financial results also shed light on its segment-wise performance:

1. Capsules Segment:

   • Revenue for Q2 FY 2025-26: Rs. 4,458.02 lakhs
   • Segment Results (Profit before tax and interest): Rs. 514.96 lakhs

2. API Segment:

   • Revenue for Q2 FY 2025-26: Rs. 122.24 lakhs
   • Segment Results: Rs. 859.45 lakhs

The API segment, despite lower revenue, showed higher profitability compared to the capsules segment, indicating its potential as a growth driver for the company.

Financial Position

As of September 30, 2025, Natural Capsules Limited's consolidated balance sheet reflected:

• Total Assets: Rs. 41,995.52 lakhs
• Total Equity: Rs. 24,539.98 lakhs
• Total Liabilities: Rs. 17,855.50 lakhs

Outlook

While the standalone business remains profitable, the consolidated performance underscores the challenges faced by the subsidiary. The company's decision to abstain from the subsidiary's rights issue suggests a cautious approach to capital allocation, possibly focusing on strengthening its core operations and managing ongoing project commitments.

As Natural Biogenex Private Limited progresses towards achieving its full revenue potential, investors and stakeholders will likely keep a close watch on the consolidated performance in the coming quarters.

Natural Capsules Limited continues to navigate through a phase of strategic growth and operational consolidation, balancing the performance of its established capsules business with the evolving dynamics of its newer ventures in the pharmaceutical sector.

Natural Capsules , a leading manufacturer of hard capsule shells, held its 32nd Annual General Meeting (AGM) on August 4, 2025, where shareholders approved several significant resolutions shaping the company's governance and future direction.

Board Continuity and Reappointments

Shareholders gave their nod to the continuation of Mr. Tekkar Yashwanth Prabhu as a Non-Executive Independent Director beyond the age of 75 years until the expiry of his current term. Mr. Prabhu, with over four decades of banking experience, brings valuable expertise to the board, having served in senior positions at Canara Bank, Union Bank of India, and Oriental Bank of Commerce.

The meeting also saw the reappointment of Mr. Sathyanarayana Mundra as Whole Time Director for a three-year term, effective September 20, 2025, along with a revision in his remuneration. Mr. Mundra, responsible for quality control of products, will continue to play a crucial role in the company's operations.

New Appointments

In a move to strengthen its corporate governance, the company appointed Mr. R. Parthasarathy as Secretarial Auditor for a period of five consecutive years, from the financial year 2025-26 to 2029-30. Mr. Parthasarathy, a practicing Company Secretary with 38 years of experience in company law matters, brings extensive expertise to this role.

Other Key Resolutions

The AGM also addressed several other important matters:

1. Adoption of audited financial statements for the year ended March 31, 2025.
2. Reappointment of Mr. Sushil Kumar Mundra as a director, who was retiring by rotation.
3. Approval of related party transactions with the subsidiary, Natural Biogenex Private Limited.
4. Approval for the payment of commission to Non-Executive Directors.

Voting Results

All resolutions put forth at the AGM were passed with overwhelming majority. The e-voting results showed 100% votes in favor for most resolutions, indicating strong shareholder support for the company's decisions.

Management's Perspective

While specific comments from the management were not provided, the approval of these resolutions suggests a focus on maintaining experienced leadership, enhancing corporate governance, and preparing for future growth.

Natural Capsules, known for pioneering the manufacturing of vegetarian capsules in India, continues to evolve its governance structure to support its position as a key player in the pharmaceutical industry. These board-level changes and appointments are likely aimed at steering the company through its next phase of growth and expansion.